Table 1.
Demographic and clinical characteristics of the patients.
| Experimental | Control | All | p-Value | |
|---|---|---|---|---|
| Patients | 10 (50.0%) | 10 (50.0%) | 20 (100%) | |
| Age | 49.0 (10.0) | 53.4 (10.7) | 52.5 (10.4) | 0.24 |
| Education | 11.3 (3.3) | 11.6 (0.8) | 11.9 (4.9) | 0.98 |
| Sex | ||||
| Male | 8 (80.0%) | 2 (20.0%) | 10 (50.0%) | 0.007 |
| Female | 2 (20.0%) | 8 (80.0%) | 10 (50.0%) | |
| Disease duration, (years) | 10.7 (5.3) | 10.1 (6.1) | 10.5 (5.8) | 0.68 |
| Median EDSS | 4.7 (1.4) | 4.9 (0.4) | 4.8 (1.0) | 0.41 |
| Therapy | ||||
| Avonex | 3 (30.0%) | 2 (20.0%) | 5 (25.0%) | 0.85 |
| Tecfidera | 2 (20.0%) | 3 (30.0%) | 5 (25.0%) | |
| Natalizumab | 3 (30.0%) | 3 (30.0%) | 6 (30.0%) | |
| Alemtuzumab | 2 (20.0%) | 0 (0.00) | 2 (10.0%) | |
| Fingolimod | 0 (0.00) | 2 (20.0%) | 2 (10.0%) |
Mean (standard deviation) was used to describe continuous variables; proportions (numbers and percentages) were used to describe categorical variables.